A TRIM37 risk variant rs57141087 contributes to triple-negative breast cancer onset and progression in Black women.
RNA-seq (gene expression) · human · 28 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 28 samples: 7 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- The TRIM37 variant rs57141087 contributes to triple-negative breast cancer outcomes in Black womenEMBO reports · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE277029_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1160264 and SRA study SRP532384. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 28 samples.
How we read this: 7 replicated groups read from 28 sample titles; they account for 28 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8512961 KTB51, rs57141087 rep1 KTB51, rs57141087
- GSM8512962 KTB51, rs57141087 rep2 KTB51, rs57141087
- GSM8512963 KTB51, Control rep1 KTB51, Control
- GSM8512964 KTB51, Control rep2 KTB51, Control
- GSM8512965 KTB51, TRIM37 rep1 KTB51, TRIM37
- GSM8512966 KTB51, TRIM37 rep2 KTB51, TRIM37
- GSM8512967 KTB39, Control rep1 KTB39, Control
- GSM8512968 KTB39, Control rep2 KTB39, Control
- GSM8512969 KTB39, TRIM37 rep1 KTB39, TRIM37
- GSM8512970 KTB39, TRIM37 rep2 KTB39, TRIM37
- GSM8512971 K105166 K
- GSM8512972 K105180 K
- GSM8512973 K105392 K
- GSM8512974 K105440 K
- GSM8512975 K106165 K
- GSM8512976 K106473 K
- GSM8512977 K107799 K
- GSM8512978 K107908 K
- GSM8512979 K107975 K
- GSM8512980 K108617 K
- GSM8512981 K108875 K
- GSM8512982 K109067 K
- GSM8512983 Sample_1 Sample
- GSM8512984 Sample_2 Sample
- GSM8512985 Sample_3 Sample
- GSM8512986 Sample_4 Sample
- GSM8512987 Sample_5 Sample
- GSM8512988 Sample_6 Sample
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing · shares progression, breast
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing · shares breast
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing · shares breast
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing · shares breast
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE234324 CRISPR-Enabled Profiling of Enhancer RNA-Producing Super-Enhancers in Triple-Negative Breast Cancer Identifies Drivers of Tumor Progression [RNA-Seq] 104 samples shares triple-negative, progression, breast
- GSE234328 CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression 108 samples shares triple-negative, progression, breast
- GSE261988 SWI/SNF is a gatekeeper of chromatin access at enhancer networks controlling triple-negative breast cancer progression [ChIP-Seq] 79 samples shares triple-negative, progression, breast
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.